ETFIQData as of Nov 18, 2026. · etfiq.com/funds/sbio

SBIO Fact Sheet: ALPS Medical Breakthroughs ETF

Share
$52.90
close, Nov 18, 2026

Over the year to Nov 18, 2026, SBIO returned +13.0% in total and charged 0.50% a year.

1-year total return
+13.0%
to Nov 18, 2026
Expense ratio
0.50%
a year
Net flow, 12 months to Aug 31, 2026
+$81.7m
monthly N-PORT basis to Aug 31, 2026

Growth of $10,000, 1 year

SBIO $11,304 +13.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+1.5%
3 months−25.3%
Year to date+3.3%
1 year+13.0%
3 years+114.9%
5 years+22.1%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Crinetics Pharmaceuticals Inc4.60%
Apogee Therapeutics Inc4.29%
Cg Oncology Inc3.41%
Travere Therapeutics Inc3.17%
Xenon Pharmaceuticals Inc2.99%
Dianthus Therapeutics Inc2.96%
Oruka Therapeutics Inc2.87%
Acadia Pharmaceuticals Inc2.54%
Edgewise Therapeutics Inc2.31%
Definium Therapeutics Inc2.23%

SBIO top ten by weight, 31.4% of the fund, of its 103 equity positions, from the holdings filed for Aug 31, 2026.

Facts

Equity fund · Tracks the S-Network Medical Breakthroughs Index · First traded Dec 31, 2014 · Benchmark Its own holdings, as of Aug 31, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, SBIO Fact Sheet: ALPS Medical Breakthroughs ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/sbio/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/sbio.